How GLP-1s are paving the way for the new era of biotech - Elliot Hershberg, Investor & Blogger

<p>Elliot Hershberg is a partner at Amplify Partners and author of the popular blog Century of Biology. In this episode, we talk about GLP-1s as a breakthrough moment for biotech, why drug development is starting to behave like software, and how falling discovery costs could finally free biotech startups from selling themselves to pharma.</p><p>We also talk about Elliot’s &quot;massive markets, medium prices&quot; thesis, the rise of consumer and &quot;n-of-one&quot; medicine, and Sid Sijbrandij going founder mode on his cancer by measuring himself, using AI to build a pipeline of personalized therapies, and is now disease-free. </p><p>Thank you to SynBioBeta for hosting us at their conference, where we recorded this episode, and several others we’ll be releasing soon!</p><p>Check out Elliot&#39;s blog at centuryofbio.com</p>